Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer
Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment. Read More
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant survival advantage for patients with folate receptor ... Read More
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More
Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at ... Read More